Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users

Addiction

Volumn 106, Issue 7, 2011, Pages 1293-1300

  Morefield, Kate M ^a   Keane, Michael ^a   Felgate, Peter ^b   White, Jason M ^a,c   Irvine, Rodney J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b FORENSIC SCIENCE SA   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

3; 4 methylenedioxymethamphetamine; Drug concentrations; Drug dose; Ecstasy; MDMA; Pill content

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; PSYCHEDELIC AGENT;

ADULT; ARTICLE; AUSTRALIA; BLOOD; BRAIN; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; METHODOLOGY; RISK FACTOR; SUBSTANCE ABUSE; TABLET; TIME;

ADULT; AUSTRALIA; BRAIN; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, GAS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HALLUCINOGENS; HUMANS; MALE; MASS SPECTROMETRY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RISK FACTORS; SUBSTANCE ABUSE DETECTION; TABLETS; TIME FACTORS; YOUNG ADULT;

EID: 79957974356     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03399.x     Document Type: Article

References (50)

1. Schwartz R. H., Miller N. S. MDMA (ecstasy) and the rave: a review. Pediatrics 1997; 100: 705-8.
2. Boys A., Lenton S., Norcross K. Polydrug use at raves by a Western Australian sample. Drug Alcohol Rev 1997; 16: 227-34.
3. Winstock A. R. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001; 64: 9-17.
4. Boeri M. W., Sterk C. E., Elifson K. W. Rolling beyond raves: ecstasy use outside the rave setting. J Drug Issues 2004; 34: 831-59.
5. Degenhardt L., Barker B., Topp L. Patterns of ecstasy use in Australia: findings from a national household survey. Addiction 2004; 99: 187-95.
6. Davison D., Parrott A. C. Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol Clin Exp 1997; 12: 221-6.
7. Schifano F. A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berl) 2004; 173: 242-8.
8. Schifano F. Death rates from ecstasy(MDMA, MDA) and polydrug use in England and Wales 1996-2002. Hum Psychopharmacol 2003; 18: 519-24.
9. Camilleri A. M., Caldicott D. Underground pill testing, down under. Forensic Sci Int 2005; 151: 53-8.
10. Green A. R., Mechan A. O., Elliott J. M., O'Shea E., Colado M. I. The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 2003; 55: 463-508.
11. Easton N. Ecstasy: are animal data consistent between species and can they translate to humans? J Psychopharmacol 2006; 20: 194-210.
12. de la Torre R., Farre M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 2004; 25: 505-8.
13. Kalechstein A. D., De La Garza R. II, Mahoney J. J. III, Fantegrossi W. E., Newton T. F. MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl) 2007; 189: 531-7.
14. Ricaurte G. A., Yuan J., McCann U. D. (+/-)3, 4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 2000; 42: 5-10.
15. McCann U., Szabo Z., Vranesic M., Palermo M., Mathews W., Ravert H. etal. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (±) 3, 4-methylenedioxymethamphetamine ('ecstasy') users: relationship to cognitive performance. Psychopharmacology (Berl) 2008; 200: 439-50.
16. Lamers C., Bechara A., Rizzo M., Ramaekers J. Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls. J Psychopharmacol 2006; 20: 302-11.
17. Sumnall H., Cole J. Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis. J Psychopharmacol 2005; 19: 84-92.
18. de Win M. M. L., Jager G., Booij J., Reneman L., Schilt T., Lavini C. etal. Neurotoxic effects of ecstasy on the thalamus. Br J Psychiatry 2008; 193: 289-96.
19. McCann U. D. Positron emission tomographic evidence of toxic effect of MDMA ('Ecstasy') on brain serotonin neurons in human beings. Lancet 1998; 352: 1433-7.
20. McCann U. D., Szabo Z., Seckin E., Rosenblatt P., Mathews W. B., Ravert H. T. etal. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [(11)C]McN5652 and [(11)C]DASB. Neuropsychopharmacology 2005; 30: 1741-50.
21. Gouzoulis-Mayfrank E., Daumann J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 2006; 101: 348-61.
22. Thomasius R., Zapletalova P., Petersen K., Buchert R., Andresen B., Wartberg L. etal. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 2006; 1: 211-25.
23. Cole J. C., Bailey M., Sumnall H. R., Wagstaff G. F., King L. A. The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 2002; 97: 1531-6.
24. Parrott A. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. J Psychopharmacol 2006; 20: 147-63.
25. Kolbrich E., Goodwin R., Gorelick D., Hayes R., Stein E., Huestis M. Physiological and subjective responses to controlled oral MDMA administration. J Clin Psychopharmacol 2008; 28: 432-0.
26. Irvine R. J., Keane M., Felgate P., McCann U. D., Callaghan P. D., White J. M. Plasma drug concentrations and physiological measures in 'dance party' participants. Neuropsychopharmacology 2005; 31: 424-30.
27. de la Torre R., Farre M., Roset P. N., Pizarro N., Abanades S., Segura M. etal. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 2004; 26: 137-44.
28. Kolbrich E. A., Goodwin R. S., Gorelick D. A., Hayes R. J., Stein E. A., Huestis M. A. Plasma pharmacokinetics of 3, 4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 2008; 30: 320-32.
29. Mas M., Farré M., de la Torre R., Roset P. N., Segura J. O. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999; 290: 136-45.
30. Solowij N., Hall W., Lee N. Recreational MDMA use in Sydney: a profile of 'ecstasy' users and their experiences with the drug. Addiction 1992; 87: 1161-72.
31. Topp L., Hando J., Dillon P., Roche A., Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999; 55: 105-15.
32. Scholey A. B., Parrott A. C., Buchanan T., Heffernan T. M., Ling J., Rodgers J. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study. Addict Behav 2004; 29: 743-52.
33. Australian Institute of Health and Welfare (AIHW). 2007 National Drug Strategy Household Survey: Detailed Findings. Canberra: AIHW; 2008.
34. Kalasinsky K. S. Use of MDA (the 'love drug') and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). J Forensic Sci 2004; 49: 1106-12.
35. Kaye S., Darke S., Duflou J. Methylenedioxymethamphetamine (MDMA)-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Drug Alcohol Depend 2009; 104: 254-61.
36. Gowing L. R., Henry-Edwards S. M., Irvine R. J., Ali R. L. The health effects of ecstasy: a literature review. Drug Alcohol Rev 2002; 21: 53-63.
37. Tanner-Smith E. E. Pharmacological content of tablets sold as 'ecstasy': results from an online testing service. Drug Alcohol Depend 2006; 83: 247-54.
38. Fox H. C. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol 2001; 15: 273-81.
39. Green A. R., Gabrielsson J., Marsden C. A., Fone K. C. F. MDMA: on the translation from rodent to human dosing. Psychopharmacology (Berl) 2009; 204: 375-8.
40. Kalant H. The pharmacology and toxicology of 'ecstasy' (MDMA) and related drugs. CMAJ 2001; 165: 917-28.
41. Pacifici R., Zuccaro P., Farre M., Pichini S., Di Carlo S., Roset P. N. etal. Effects of repeated doses of MDMA ('ecstasy') on cell-mediated immune response in humans. Life Sci 2001; 69: 2931-41.
42. Farre M., de la Torre R., Mathuna B. O., Roset P. N., Peiro A. M., Torrens M. etal. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 2004; 173: 364-75.
43. Baumann M., Zolkowska D., Kim I., Scheidweiler K., Rothman R., Huestis M. Effects of dose and route of administration on pharmacokinetics of ({+/-})-3, 4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos 2009; 37: 2163-70.
44. Mueller M., Peters F. T., Maurer H. H., McCann U. D., Ricaurte G. A. Nonlinear pharmacokinetics of ({+/-})3, 4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its major metabolites in squirrel monkeys at plasma concentrations of MDMA that develop after typical psychoactive doses. J Pharmacol Exp Ther 2008; 327: 38-44.
45. Tancer M. E., Johanson C. E. The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 2001; 65: 97-101.
46. Lamers C. T., Ramaekers J. G., Muntjewerff N. D., Sikkema K. L., Samyn N., Read N. L. etal. Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharmacol 2003; 17: 379-87.
47. Parrott A. C. Chronic tolerance to recreational MDMA (3, 4-methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol 2005; 19: 71-83.
48. Freudenmann R., Spitzer M. The neuropsychopharmacology and toxicology of 3, 4-methylenedioxy-N-ethyl-amphetamine (MDEA). CNS Drug Rev 2004; 10: 89-116.
49. Winstock A. R., Wolff K., Ramsey J. Ecstasy pill testing: harm minimization gone too far? Addiction 2001; 96: 1139-48.
50. Hayner G. N. MDMA misrepresentation: an unresolved problem for Ecstasy users. J Psychoactive Drugs 2002; 34: 195-8.